Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience

Overview of attention for article published in International Journal of Hematology, September 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 15 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 3 news stories from 1 outlets.

ITP: Is Rituximab Superior to Splenectomy as A Second-line Therapy?

Oncology Nurse Advisor , 26 Sep 2017

September 26, 2017 Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line…

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Oncology Nurse Advisor , 21 Sep 2017

September 21, 2017 For patients who are refractory to primary treatment, splenectomy or rituximab have been as effective as…

Rituximab vs Splenectomy: Response Similar in Immune Thrombocytopenic Purpura

Oncology Nurse Advisor , 21 Sep 2017

September 21, 2017 For patients who are refractory to primary treatment, splenectomy or rituximab have been as effective as…